Literature DB >> 26244858

Clozapine prescription and quality of life in Chinese patients with schizophrenia treated in primary care.

C-L Hou1, M-Y Cai2, X-R Ma3, Y Zang4, F-J Jia1, Y-Q Lin1, H F K Chiu5, G S Ungvari6, C H Ng7, B-L Zhong5, X-L Cao4, Y Li5, N Shinfuku8, Y-T Xiang9.   

Abstract

OBJECTIVE: Clozapine is frequently used to treat schizophrenia in China. Maintenance treatment for clinically stable patients with schizophrenia is usually provided by Chinese primary care physicians, but no study has investigated the frequency of its use prescribed by primary care physicians. This study described the frequency, demographic and clinical characteristics of clozapine treatment and its impact on insight and quality of life (QOL) of patients with schizophrenia treated in primary care in China.
METHOD: A total of 623 patients with schizophrenia treated in 22 primary care services in Guangzhou, China in 2013 formed the study sample. Patients' socio-demographic and clinical characteristics including psychopathology, medication side effects and QOL were recorded using a standardized protocol and data collection.
RESULTS: The frequency of clozapine prescription was 35.6% with a mean daily dose of 127.7±88.2 mg. There were no significant differences between the patients with and without clozapine in either of the QOL domains after controlling the confounding factors. Multiple logistic regression analyses revealed that patients on clozapine had younger age of onset, more hospitalizations, more severe extrapyramidal side effects, but better insight and fewer prescriptions of first generation antipsychotics.
CONCLUSIONS: Clozapine use was found to be common and associated with better insight in patients with schizophrenia treated in primary care in China. Further examination of the rationale and appropriateness of clozapine in primary care in China is warranted. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26244858     DOI: 10.1055/s-0035-1555939

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments.

Authors:  Paul H Lysaker; Michelle L Pattison; Bethany L Leonhardt; Scott Phelps; Jenifer L Vohs
Journal:  World Psychiatry       Date:  2018-02       Impact factor: 49.548

2.  Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine.

Authors:  Xiaoping Yuan; Song Wang; Yudong Shi; Yating Yang; Yulong Zhang; Lei Xia; Kai Zhang; Huanzhong Liu
Journal:  Psychopharmacology (Berl)       Date:  2022-01-26       Impact factor: 4.530

3.  Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.

Authors:  Paul H Lysaker; Peter J Weiden; Xiaowu Sun; Amy K O'Sullivan; Joseph P McEvoy
Journal:  BMC Psychiatry       Date:  2022-08-28       Impact factor: 4.144

4.  Psychotropic medication treatment patterns in community-dwelling schizophrenia in China: comparisons between rural and urban areas.

Authors:  Cai-Lan Hou; Shi-Bin Wang; Fei Wang; Ming-Zhi Xu; Miao-Yang Chen; Mei-Ying Cai; Yao-Nan Xiao; Fu-Jun Jia
Journal:  BMC Psychiatry       Date:  2019-08-05       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.